Medivir’s series A shares to be converted into series B shares
Stockholm, Sweden — Medivir AB (publ) (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) today announces that the holders of series A shares have notified the Company that they will convert all their series A shares in Medivir to series B shares. The conversion will be completed as soon as possible following the Extraordinary General Meeting in Medivir to be held on 26 January 2018.Following the conversion, there will no longer be any series A shares outstanding in Medivir. The total number of shares in Medivir will not be affected, but all outstanding shares will be series B shares.